Evidence map›Paper›PMID 35087526›Full record

ArticleFrontiers in immunology2021

Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.

Daniel Klewinghaus, Lukas Pekar, Paul Arras, Simon Krah, Bernhard Valldorf, Harald Kolmar, Stefan Zielonka

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Enhancing NK cell-mediated tumor killing of B7-H6Molecular therapy. Oncology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. The impact of exchanging the light and heavy chains on the structures of bovine ultralong antibodies.Acta crystallographica. Section F, Structural biology communications · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Daniel KlewinghausProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Lukas PekarProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Paul ArrasProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Simon KrahProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Bernhard ValldorfChemical and Pharmaceutical Development, Merck KGaA, Darmstadt, Germany.
Harald KolmarInstitute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany.
Stefan ZielonkaProtein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Merck (Germany) · DETechnical University of Darmstadt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A subset of antibodies found in cattle comprises ultralong CDR-H3 regions of up to 70 amino acids. Interestingly, this type of immunoglobulin usually pairs with the single germline VL gene, V30 that is typically very conserved in sequence. In this work, we have engineered ultralong CDR-H3 common light chain bispecific antibodies targeting Epidermal Growth Factor Receptor (EGFR) on tumor cells as well as Natural Cytotoxicity Receptor NKp30 on Natural Killer (NK) cells. Antigen-specific common light chain antibodies were isolated by yeast surface display by means of pairing CDR-H3 diversities following immunization with a single V30 light chain. After selection, EGFR-targeting paratopes as well as NKp30-specific binders were combined into common light chain bispecific antibodies by exploiting the strand-exchange engineered domain (SEED) technology for heavy chain heterodimerization. Biochemical characterization of resulting bispecifics revealed highly specific binding to the respective antigens as well as simultaneous binding to both targets. Most importantly, engineered cattle-derived bispecific common light chain molecules elicited potent NK cell redirection and consequently tumor cell lysis of EGFR-overexpressing cells as well as robust release of proinflammatory cytokine interferon-γ. Taken together, this data is giving clear evidence that bovine bispecific ultralong CDR-H3 common light chain antibodies are versatile for biotechnological applications.

Indexed as

Antibody SpecificityAnimalsAntibodies, BispecificBinding Sites, AntibodyCattleComplementarity Determining RegionsCytokinesCytotoxicity, ImmunologicErbB ReceptorsHumansImmunoglobulin Fab FragmentsImmunoglobulin Light ChainsInflammation MediatorsKiller Cells, NaturalNatural Cytotoxicity Triggering Receptor 3Protein EngineeringAntibodies, BispecificComplementarity Determining RegionsCytokinesErbB ReceptorsImmunoglobulin Fab FragmentsImmunoglobulin Light ChainsInflammation MediatorsNatural Cytotoxicity Triggering Receptor 3NCR3 protein, humanRecombinant Fusion Proteinsantibody engineeringbispecific antibodiesbovine ultralong CDR-H3 antibodiescommon light chaineffector cell redirectionNK cell engagersyeast surface display

Identifiers

PMID35087526
PMCPMC8787767
OpenAlexW4205620457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.